News
Osteoporosis. ACR novelties within the framework of the rheumatology school
11.12.2020

The company "Ananta Medicare" supported the holding of the rheumatology school and took part in it. More than 1,500 doctors have got acquainted with the materials of the school remotely.

Antibiotics can treat dementia
10.12.2020

Scientists from the United States have found that a certain class of antibiotics could be promising for the treatment of frontotemporal dementia.

New toxoplasmosis vaccine
07.12.2020

By using a new approach, scientists have developed an experimental vaccine against Toxoplasma gondii.

A two-vaccine regimen may provide the best protection against Ebola virus
03.12.2020

A study has shown that sequential administration of two different Ebola virus vaccines at regular intervals may provide the best immune response.

EMA may approve new gene therapy product by Bluebird Bio Company
30.11.2020

European Medicines Agency is considering the application of the American Bluebird Bio for the registration of cerebral adrenoleukodystrophy drug.

To save pharmacists' time a RTEC is being tested in Britain
26.11.2020

Department of the National Health Service of UK in association with the NHS Business Services Authority have developed RTEC based drug dispensing platform.

The effectiveness of an anticoagulant in stroke has been proven
23.11.2020

The FDA has approved the anticoagulant Brilinta for use in patients with cardiovascular disease.

The drug for amyotrophic lateral sclerosis has impressed neurologists
19.11.2020

In a small study, a biotech company has tested its own amyotrophic lateral sclerosis drug.

Osteoporosis - From Idea to Action. Zoleum.
13.11.2020

On 22nd of September 2020 the company "Ananta Medicare" in association with "Clinic of modern rheumatology" held the first webinar on the topic of osteoporosis. The lecture "Osteoporosis - from idea to action" was conducted by prof. Egudina Elizaveta Davydovna.

Swiss company is interested in finding new drug targets
20.10.2020

Scenic Biotech founders and biologists have designed their own functional genomics platform to accurately identify genes that modify a specific disease.